Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 2/20 | 0.42 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.40 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28852802 | 0.81 | MMP2 (0.45) | ANPEP | |
| SCHEMBL4368473 | 0.80 | BLM (0.48) | BLMLMNACYP3A4NFKB1PMP22 | |
| SCHEMBL371406 | 0.77 | CYP1A2 (0.36) | BLMLMNACYP3A4NFKB1PMP22 | |
| SCHEMBL9564515 | 0.76 | BLM (0.46) | BLMLMNACYP3A4NFKB1PMP22 | |
| SCHEMBL371460 | 0.76 | DRD3 (0.31) | BLMDRD3CYP1A2THPO | |
| SCHEMBL23631719 | 0.76 | MMP2 (0.46) | ANPEP | |
| SCHEMBL9792360 | 0.74 | ANPEP (0.36) | ANPEPALDH1A1TDP1 | |
| SCHEMBL371407 | 0.73 | MEN1 (0.35) | CYP3A4CYP1A2TSHRTDP1 | |
| SCHEMBL3795216 | 0.72 | BLM (0.50) | BLMLMNACYP3A4NFKB1PMP22 | |
| SCHEMBL10456626 | 0.72 | ANPEP (0.37) | BLMLMNACYP3A4NFKB1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120116074-A1 | METHODS FOR THE PREPARATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7)-EN-2-YL)ETHYL]PHOSPHONIC ACID AND PRECURSORS THEREOF | CULLEN THOMAS GERARD (US) | 2012-05-10 | — | — | US | claimed |
| EP-2408790-A1 | METHODS FOR THE PREPARATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7)-EN-2-YL)ETHYL]PHOSPHONIC ACID AND PRECURSORS THEREOF | Wyeth LLC (US) | 2012-01-25 | — | — | EP | claimed |
| WO-2010108063-A1 | METHODS FOR THE PREPARATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7)-EN-2-YL)ETHYL]PHOSPHONIC ACID AND PRECURSORS THEREOF | WYETH LLC (US) | 2010-09-23 | — | — | WO | claimed |
| US-20120116074-A1 | METHODS FOR THE PREPARATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7)-EN-2-YL)ETHYL]PHOSPHONIC ACID AND PRECURSORS THEREOF | CULLEN THOMAS GERARD (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2408790-A1 | METHODS FOR THE PREPARATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7)-EN-2-YL)ETHYL]PHOSPHONIC ACID AND PRECURSORS THEREOF | Wyeth LLC (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010108063-A1 | METHODS FOR THE PREPARATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7)-EN-2-YL)ETHYL]PHOSPHONIC ACID AND PRECURSORS THEREOF | WYETH LLC (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116074-A1 | METHODS FOR THE PREPARATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7)-EN-2-YL)ETHYL]PHOSPHONIC ACID AND PRECURSORS THEREOF | DERA, ENO1, PPIP5K2 | BLM 4337/4885LMNA 1428/4885CYP3A4 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.